Immunomodulatory peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
In 1965, forensic characterization of psilocybin-containing mushrooms seized from college students in British Columbia identified P. semilanceata—the first recorded case of intentional recreational use of the mushroom in Canada. The presence of the psilocybin analog baeocystin was confirmed in 1977. Several studies published since then support the idea that the variability of psilocybin content in P. semilanceata is low, regardless of country of origin.
==== Military reforms ==== Since taking power in 2012, Xi has undertaken an overhaul of the People's Liberation Army, including both political reform and its modernization. Military-civil fusion has advanced under Xi. Xi has been active in his participation in military affairs, taking a direct hands-on approach to military reform. In addition to being the chairman of the CMC and leader of the Central Leading Group for Military Reform founded in 2014 to oversee comprehensive military reforms, Xi has delivered numerous high-profile pronouncements vowing to clean up malfeasance and complacency in the military. Xi has repeatedly warned that the depoliticization of the PLA from the CCP would lead to a collapse similar to that of the Soviet Union. Xi held the New Gutian Conference in 2014, gathering China's top military officers, re-emphasizing the principle of "the party has absolute control over the army" first established by Mao at the 1929 Gutian Congress. Xi's tenure saw an emphasis on the chairman responsibility system, highlighting the CMC chairman's absolute leadership over the Central Military Commission and the military.
In the 1990s, the German Federal Intelligence Service (BND) obtained a sample of one Novichok agent from a Russian scientist, and the sample was analysed in Sweden, according to a 2018 Reuters report. The chemical formula was given to Western NATO countries, who synthesized it, then used small amounts to test protective equipment, detection of it, and antidotes to it. Novichok was referred to in a patent filed in 2008 for an organophosphorus poisoning treatment. The University of Maryland, Baltimore research was funded in part by the U.S. Army. Professor Leonid Rink, who said he had participated in the creation of Novichok agents, confirmed that the structures leaked by Mirzayanov were the correct ones. Rink was himself convicted in Russia for illegally selling a Novichok agent used in 1995 to assassinate a banker, Ivan Kivelidi, and his secretary. David Wise, in his book Cassidy's Run, implies that the Soviet program may have been the unintended result of misleading information, involving a discontinued American program to develop a nerve agent code named "GJ", that was fed by a double agent to the Soviets as part of Operation Shocker.
4-HO-DPT, also known as 4-hydroxy-N,N-dipropyltryptamine or as deprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. The drug is closely structurally related to other psychedelic tryptamines such as dipropyltryptamine (DPT), 5-MeO-DPT, and psilocin (4-HO-DMT), among others. 4-HO-DPT was first described in the scientific literature by David Repke and colleagues in 1977. It was encountered as a novel designer drug in 2012. A presumed prodrug, 4-AcO-DPT, is also known, and has likewise been encountered as a designer drug.
=== Rowing === New Zealand Secondary School Championships (Maadi Cup) Maadi Cup (boys' U18 eight) – Westlake Boys High School Levin Jubilee Cup (girls' U18 eight) – St Margaret's College Star Trophy (overall points) – King's College
Sources: en.wikipedia.org
Sensory gating A process by which the brain filters out redundant or unnecessary stimuli from all the sensory inputs, often studied in schizophrenia research. Sensory map An organized representation of sensory information in the brain. For example, the somatotopic map in the primary somatosensory cortex. Serotonin A neurotransmitter involved in mood, sleep, appetite, and cognition. Dysregulation of serotonin systems is linked to depression and anxiety disorders. Short-term memory The capacity to hold a small amount of information in an active, readily accessible state for a short period of time. Often contrasted with long-term memory. Sleep spindle A burst of oscillatory brain activity visible on an EEG during Stage 2 non-REM sleep. Thought to play a role in memory consolidation. Somatic nervous system A component of the peripheral nervous system responsible for voluntary control of body movements via skeletal muscles. Somatosensory system The part of the sensory system concerned with the conscious perception of touch, pressure, pain, temperature, position, movement, and vibration. Spasticity A condition of increased muscle tone (hypertonia) and exaggerated reflexes, often resulting from damage to upper motor neurons. Spatial memory The part of memory responsible for recording information about one’s environment and spatial orientation. Heavily dependent on the hippocampus. Spike-timing-dependent plasticity (STDP) A form of synaptic plasticity in which the timing of neuronal spikes determines whether synapses are strengthened or weakened.
=== Governmental districts (Regierungsbezirke) === The large states of Baden-Württemberg, Bavaria, Hesse, and North Rhine-Westphalia are divided into governmental districts, or Regierungsbezirke. In Rhineland-Palatinate, these districts were abolished or re-organized on 1 January 2000, in Saxony-Anhalt on 1 January 2004, and in Lower Saxony on 1 January 2005. From 1990 until 2012, Saxony was divided into three districts (called Direktionsbezirke since 2008). In 2012, these districts' authorities were merged into one central authority, the Landesdirektion Sachsen.
=== Blood tests === When RA is clinically suspected, a physician may test for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs measured as anti-CCP antibodies). The test is positive approximately two-thirds of the time, but a negative RF or CCP antibody does not rule out RA; rather, the arthritis is called seronegative, which occurs in approximately a third of people with RA. During the first year of illness, rheumatoid factor is more likely to be negative with some individuals becoming seropositive over time. RF is a non-specific antibody and seen in about 10% of healthy people, in many other chronic infections like hepatitis C, and chronic autoimmune diseases such as Sjögren's disease and systemic lupus erythematosus. Therefore, the test is not specific for RA. Hence, new serological tests check for anti-citrullinated protein antibodies ACPAs. These tests are again positive in 61–75% of all RA cases, but with a specificity of around 95%. As with RF, ACPAs are many times present before symptoms have started. The by far most common clinical test for ACPAs is the anti-cyclic citrullinated peptide (anti CCP) ELISA. In 2008, a serological point-of-care test for the early detection of RA combined the detection of RF and anti-MCV with a sensitivity of 72% and specificity of 99.7%. To improve the diagnostic capture rate in the early detection of patients with RA and to risk-stratify these individuals, the rheumatology field continues to seek complementary markers to both RF and anti-CCP.
=== Temperature === Conversion of both CO and CO2 to CH4 starts at a catalyst temperature below 300°C, but the conversion is incomplete and peak tailing is evident. At around 340°C, conversion is complete, as indicated by area measurements, but some tailing limits the peak height. At 360-380°C, tailing is eliminated and there is little change in peak height up to 400°C. Operating temperatures for various methanizers range from 350-400°C. Although carbonization of CO has been reported at temperatures above 350°, it is rather a rare phenomenon.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.